AGM filled w details plus potential minor sht-term catalystsFew tidbits in no particular order: - BLA fee waiver (all or majority of fee) applied to via two other sources. Expect an answer prior to BLA filing. -Third party commercial assessment of market and pricing s/b known by end of Nov/early Dec. Important to maximize partnering discussions. - Current estimate for cost per MCNA dose $3,000 and number of doses 15 to 24. Also mentioned "very high profit margin". - Assessment of Montreal production facility (for MCNA) also underway (and needed for FDA). Goal is also to be in production if/when BLA approved. No major deficiencies expected. - Meeting with two PR-type firms following AGM (i.e., this aft). Comprehensive campaign to raise awareness across the spectrum of parties of interest (investment bankers --> Joe/Mary investor). - Expect 2-3 new analyst reports out by end of this 2014 (if I heard timing correctly). - Telesta approved. Graphic look great. Transition s/b noticeable asap (possibly starting in a week). Expect launch of new website. - Mr. Gubitz did not receive necessary votes to be elected/continue as a Director. - Target partner in U.S. appears more likely a mid size pharma/ biotech with experience, sales force and capital; albeit also discussed option of building proprietary sales force for U.S. And, a positive quote from Dr. Berendt to end this brief summary..."We think we are well positioned to go forward with FDA". Of course he also mentioned several times that approval is not guaranteed. Hopefully others will add/ confirm/ correct. And, PPT slides shown at AGM posted sooner-than-later. rg